

In re: Appln No. 09/716,146

Atty Docket: 6006-018

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-15 (previously canceled)

Claim 16 (currently amended): An endoluminal stent for delivering a bioactive agent to a situs in a body, comprising:

a plurality of structural elements forming a radially expandable cylindrical member, [at least some of] the plurality of structural elements having a wall thickness; wherein the structural elements are comprised of a first region comprising a base layer and a second region comprising a [first layer and a] second layer covering the [first] base layer, the second region further comprising a layer of void space intermediate the [first] base and second layers and enclosed therebetween;

a plurality of pores passing through at least one of the [first] base and second layers and communicating with the void space; and

at least one bioactive agent retained within the void space and elutable through the plurality of pores.

Claims 17-19 (previously canceled)

Claim 20 (previously added): The endoluminal stent according to claim 16, further comprising a degradable plug residing within the plurality of pores to prohibit release of the at least one bioactive agent until the degradation of the degradable plug.

C 1  
Claims 21-25 (previously canceled)

Claim 26 (previously added): The endoluminal stent according to claim 16, wherein the structural elements further comprises a material selected from the group consisting of titanium, vanadium, aluminum, nickel, tantalum, zirconium, chromium, silver, gold, silicon, magnesium, niobium, scandium, platinum, cobalt, palladium, manganese, molybdenum and alloys thereof, including zirconium-titanium-tantalum alloys, nitinol, and stainless steel.

Claim 27 (previously added): The endoluminal stent according to claim 16, wherein the bioactive agent further comprises a pharmacologically active agent selected from the group consisting of antibiotic drugs, antiviral drugs, neoplastic agents, steroids, fibronectin, anti-clotting drugs, anti-

In re: Appln No. 09/716,146

Any Docket: 6006-018

C1  
Cantel

platelet function drugs, drugs which prevent smooth muscle cell growth on inner surface wall of vessel, heparin, heparin fragments, aspirin, coumadin, tissue plasminogen activator, urokinase, hirudin, streptokinase, antiproliferatives, methotrexate, cisplatin, fluorouracil, adriamycin, antioxidants, ascorbic acid, beta carotene, vitamin E, antimetabolites, thromboxane inhibitors, non-steroidal and steroidal anti-inflammatory drugs, immunosuppressants, such as rapomycin, beta and calcium channel blockers, genetic materials including DNA and RNA fragments, complete expression genes, antibodies, lymphokines, growth factors, vascular endothelial growth factor and fibroblast growth factor, prostaglandins, leukotrienes, laminin, elastin, collagen, nitric oxide, and integrins.

Claim 28 (previously added): The endoluminal stent according to claim 16, wherein the void space comprises a plurality of independent internal cavities along the length of the structural elements.

BEST AVAILABLE COPY